Tonix Pharmaceuticals Appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
Key Highlights
- ➤Tonix appoints George Lederman, Ph.D., as Executive Vice President of Strategy and Transformation
- ➤Lederman will lead AI initiatives to improve efficiency and manage costs
- ➤Lederman will evaluate partnerships and licensing opportunities for clinical programs
- ➤Lederman joins from Aliaxis after divesting six assets and acquiring four companies
- ➤Tonix’s approved TONMYA treats adults with fibromyalgia
Expert Statements
Siobhan Fogarty, Chief Technical Officer of Tonix Pharmaceuticals
“We believe George’s experience in portfolio strategy and operational transformation, combined with his expertise in AI, will help us improve efficiency and pursue partnerships for select pipeline programs.”
Siobhan Fogarty, Chief Technical Officer of Tonix Pharmaceuticals
“We intend to evaluate opportunities to advance these programs with the goal of sharing development costs.”
George Lederman, Executive Vice President of Strategy and Transformation at Tonix Pharmaceuticals
“I am excited to join Tonix as it advances its commercial portfolio and development programs.”
George Lederman, Executive Vice President of Strategy and Transformation at Tonix Pharmaceuticals
“With an approved treatment for adults with fibromyalgia and investigational programs in Lyme disease prevention and immunology, I believe there is significant untapped potential across Tonix’s pipeline.”
George Lederman, Executive Vice President of Strategy and Transformation at Tonix Pharmaceuticals
“I look forward to working with the team to unlock that value through potential partnerships and other strategic transactions to create shareholder value.”
George Lederman, Executive Vice President of Strategy and Transformation at Tonix Pharmaceuticals
“Tonix’s fully integrated model also creates an opportunity to rethink how we work, with AI at the core—simplifying complex processes across development and commercialization to help bring medicines to patients more quickly and efficiently.”
BERKELEY HEIGHTS, N.J., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a fully integrated, commercial-stage biopharmaceutical company, today announced the appointment of George Lederman, Ph.D., as Executive Vice President, Strategy and Transformation, effective October 30, 2026. Dr. George Lederman brings experience in corporate and portfolio strategy, operational transformation, and applied artificial intelligence (AI) to improve efficiency and reduce costs.
At Tonix, Dr. George Lederman will lead AI initiatives across the organization to improve operational efficiency and manage costs. He will also lead business development efforts, including evaluating potential partnerships and licensing opportunities to advance the Company’s clinical programs and share development costs.
Get started
Create a free account to read the full story.